 Home > Biochemistry News > Biotechnology News > Breaking the barrier that protects tumors to help develop potential "first-in-class" therapies

Breaking the barrier that protects tumors to help develop potential "first-in-class" therapies

 Last Update: 2021-12-03
 Source: Internet
 Author: User

Tags

different types flasks

tumor associated antigen

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Parthenon Therapeutics announced that it has received $65 million in Series A financing

Approximately 50% of human cancers build a barrier against immune attack

Today, Parthenon’s partners published a pre-clinical study in Nature

DDR1 is a multi-domain collagen receptor expressed in a variety of human tumors including triple negative breast cancer (TNBC)

Researchers have demonstrated in multiple preclinical models that knocking out the DDR1 gene can not only prevent tumor growth, but also protect mice from future tumors

Reference materials:

[1] Parthenon Therapeutics Raises $65 Million in Series A Funding to Advance Oncology Programs Aimed at Reprogramming the Tumor Microenvironment.

[2] Sun, X.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express breaks the barrier to protect tumors, and US$65 million helps develop potential "first-in-class" therapies

11-14

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Breaking the barrier that protects tumors to help develop potential "first-in-class" therapies

Related Articles

Express breaks the barrier to protect tumors, and US$65 million helps develop potential "first-in-class" therapies